Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VIB4920 in Patients with Rheumatoid Arthritis
2019-003697-70Phase 2Completed
- Sponsor
- Viela Bio
- Start
- Dec 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing VIB4920 with Placebo (2 arms). Primary endpoint: Change in DAS28-CRP from baseline to Day 113. Started Dec 2019; status: completed.
02
Drugs
dazodalibep
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-003697-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003697-70.